De Swert Katelijne O, Joos Guy F
Department of Respiratory Diseases, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
Eur J Pharmacol. 2006 Mar 8;533(1-3):171-81. doi: 10.1016/j.ejphar.2005.12.066. Epub 2006 Feb 7.
The tachykinins substance P and neurokinin A are present in human airways, in sensory nerves and immune cells. Tachykinins can be recovered from the airways after inhalation of ozone, cigarette smoke or allergen. They interact in the airways with tachykinin NK1, NK2 and NK3 receptors to cause bronchoconstriction, plasma protein extravasation, and mucus secretion and to attract and activate immune cells. In preclinical studies they have been implicated in the pathophysiology of asthma and chronic obstructive pulmonary disease, including allergen- and cigarette smoke induced airway inflammation and bronchial hyperresponsiveness and mucus secretion. Dual NK1/NK2 or triple NK1/NK2/NK3 tachykinin receptor antagonists offer therapeutic potential in airway diseases such as asthma and chronic obstructive pulmonary disease.
速激肽P物质和神经激肽A存在于人类气道的感觉神经和免疫细胞中。吸入臭氧、香烟烟雾或过敏原后,气道中可检测到速激肽。它们在气道中与速激肽NK1、NK2和NK3受体相互作用,引起支气管收缩、血浆蛋白外渗和黏液分泌,并吸引和激活免疫细胞。临床前研究表明,它们与哮喘和慢性阻塞性肺疾病的病理生理学有关,包括过敏原和香烟烟雾诱导的气道炎症、支气管高反应性和黏液分泌。双重NK1/NK2或三重NK1/NK2/NK3速激肽受体拮抗剂在哮喘和慢性阻塞性肺疾病等气道疾病中具有治疗潜力。